{'fraction_non_alphanumeric': 0.026476578411405296, 'fraction_numerical': 0.024439918533604887, 'mean_word_length': 5.301282051282051, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Goals and rationale for pharmacotherapeutic approach in treating cocaine dependence: insights from basic and clinical research.

The early research conducted in the author’s laboratory from 1975 onward stemmed from the even earlier work, beginning in 1964 when the author was a member of the laboratory of Professor Vincent P. Dole at the Rockefeller Institute for Biomedical Research (now the Rockefeller University) (Dole et al. 1966; Kreek 1972, 1973a; Kreek et al. 1972). At that time, scientists were challenged to develop a treatment for opiate dependency, a problem that is still being addressed, but for which there are now three different pharmacotherapeutic approaches approved by the Food and Drug Administration (FDA), and a fourth under investigation. This chapter will review briefly some of the early concepts because they are relevant for the current major problem: developing a new medication (and possibly a variety of medications) for treating cocaine dependency.